Company Overview - Echo IQ is an AI and Medical Technology company based in Sydney, Australia, focused on improving decision-making in Cardiology through AI-driven technology and proprietary software [4]. Recent Developments - The CEO of Echo IQ, Dustin Haines, will present at the Life Sciences Virtual Investor Forum on December 11, 2025 [1][2]. - EchoSolv AS, an FDA-approved solution, has seen significant commercial traction in the U.S., with a 153% increase in echocardiograms processed from July to September 2025 [6]. - There was a 58% uplift in echocardiogram processing from September to October 2025 [6]. - The company entered into a reseller agreement with SARC MedIQ, expanding the use of EchoSolv AS through a network of hospitals and cardiology practices in the U.S. [6]. Clinical Results - Preliminary top-line clinical results from the EchoSolv HF validation study show a sensitivity of 99.5% and specificity of 91.0% in identifying patients with and without Heart Failure, respectively [6]. - The company plans to submit for FDA clearance of EchoSolv HF via the 510(k) regulatory pathway in December 2025, anticipating clearance in the first half of calendar year 2026 [6]. Market Context - Heart failure and aortic stenosis are significant health challenges in the U.S., driving over US$65 billion in annual healthcare costs [6].

Core Viewpoint - Echo IQ Limited has successfully completed clinical validation for its heart failure clinical decision support software, EchoSolv HF, in collaboration with the Mayo Clinic Platform, marking a significant milestone towards FDA clearance [1][3][9]. Company Summary - Echo IQ Limited is an AI and medical technology company based in Sydney, Australia, focused on improving decision-making in cardiology through AI-driven technology and proprietary software [11]. - The company is preparing to submit for FDA clearance of EchoSolv HF via the 510(k) regulatory pathway, with submission expected in the coming weeks [4][9]. Clinical Validation Details - The clinical validation assessed EchoSolv HF's ability to detect heart failure using an independent dataset of approximately 17,000 echocardiogram studies, achieving a sensitivity of 99.5% and specificity of 91.0% [2][3][8]. - Completion of this validation fulfills the final clinical requirement before the formal FDA submission [3][8]. Market Opportunity - Heart failure is a leading cause of rehospitalization in the US, accounting for 17% of all healthcare expenditure, with a total market size estimated at US$60 billion [5][8]. - It is projected that one in four Americans will develop heart failure in their lifetime, indicating a significant market opportunity for EchoSolv HF [5][8]. Future Plans - Following potential FDA clearance, the company plans to leverage its existing presence in the US market to promote the uptake of EchoSolv HF [6][8]. - A webinar is scheduled for November 26, 2025, where the CEO will discuss the development and progress in the US market [7][9].